SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cephalon Inc – ‘8-K’ for 9/15/98 – EX-99.2

As of:  Wednesday, 9/23/98   ·   For:  9/15/98   ·   Accession #:  1036050-98-1628   ·   File #:  0-19119

Previous ‘8-K’:  ‘8-K’ on 5/9/97 for 5/8/97   ·   Next:  ‘8-K’ on / for 12/28/98   ·   Latest:  ‘8-K’ on / for 10/14/11

  in    Show  and    Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 9/23/98  Cephalon Inc                      8-K:5,7     9/15/98    3:11K                                    Donnelley R R & S… 14/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Form 8-K for Cephalon, Inc.                            4     11K 
 2: EX-99.1     Press Release Dated September 15, 1998                 1      8K 
 3: EX-99.2     Press Release Dated September 18, 1998                 2±    10K 


EX-99.2   —   Press Release Dated September 18, 1998

EX-99.2TOCTopPreviousNextBottomJust 1st
 

Contact: Sandra Menta 610-738-6376 FOR IMMEDIATE RELEASE --------------------- Cephalon Presents Research Results from Pancreatic Cancer Studies West Chester, PA - September 18, 1998 - Cephalon, Inc. (NASDAQ: CEPH) announced today the first findings from preclinical studies of its compound, CEP-701, for the treatment of pancreatic ductal adenocarcinoma (PDAC). The results presented today at the Baltic Pancreas Meeting in Germany demonstrate that CEP-701 can significantly decrease tumor growth as well as inhibit tumor cell invasion in PDAC animal models. Pancreatic cancer is the fifth most common cause of cancer deaths in the United States. The mean survival time of this highly aggressive cancer is four to six months after diagnosis. Current treatments including chemotherapy, radiation therapy and surgery, either separately or in combination, are not sufficient to significantly increase patient survival time. As reported at today's meeting by Cephalon's Dr. Bruce A. Ruggeri, CEP-701 demonstrated anti-tumor activity in five of six pancreas tumors transplanted into mice (xenografts). Four out of six of these xenografts also demonstrated inhibition of in vivo tumor cell invasion. Cephalon scientists tested CEP-701 alone and in combination with the drug, gemcitabine, finding that dual treatment with gemcitabine was more effective in inhibiting growth of PDAC xenografts than either compound alone. CEP-701 is one of a series of specific receptor trk kinase inhibitors derived from the indolocarbazole K252a, which was originally synthesized by Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan. PDAC specimens overexpress receptor trk kinases which bind to growth factors associated with tumor growth and invasiveness. Thus, inhibition of these receptor trk kinases allows for the opportunity of therapeutic intervention. Although the findings presented today are preliminary, they provide the impetus to further investigate the role of CEP-701 as a potential therapy for pancreatic cancer. In its agreement with Kyowa Hakko, Cephalon has rights to a series of molecules, including CEP-701, in the United States and Europe. Cephalon has been developing these molecules for the potential use in treating prostate and other cancers, of which CEP-701, as an orally-active molecule, is currently in Phase 1 clinical studies in the U.S. Cephalon, Inc., headquartered in West Chester, PA, is an international biopharmaceutical company dedicated to the discovery, development and marketing of products to treat neurological disorders and cancer. In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Such statements may be identified by, among other things, the use of forward-looking terminology such as "believes," or by discussions of strategy or intention. These forward- looking statements, such as any statements regarding present or anticipated scientific progress, development of potential pharmaceutical products, manufacturing development and capabilities, and other statements regarding matters that are not historical facts, or otherwise involve beliefs or predictions. The company's performance and financial results could differ materially from those reflected in the forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in documents filed by the company with the SEC (including, but not limited to, its most recent reports on Form 8-K, Form 10-Q and Form 10-K). Given these uncertainties, current or prospective investors are cautioned not to place undue reliance on any such forward-looking statements. Furthermore, the company disclaims any obligation or intent to update any such factors or forward-looking statements to reflect future events or developments. NOTE: Cephalon's press releases are posted on the Internet at the company's Web site at http://www.cephalon.com. They are also available by fax ----------------------- 24 hours a day at no charge by calling PR Newswire's Company News On-Call at 800-758-5804, extension 134563.

Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on:9/23/98None on these Dates
9/18/98
For Period End:9/15/98
 List all Filings 
Top
Filing Submission 0001036050-98-001628   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2019 Fran Finnegan & Company.  All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., Nov. 20, 9:52:07.0am ET